Skip to main content
Clinical Trials/EUCTR2019-003215-63-FR
EUCTR2019-003215-63-FR
Active, not recruiting
Phase 1

Cultured Autologous Oral Mucosa Epithelial sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency - FEMJA for « Feuillet Epithélial de Muqueuse Jugale Autologue » - FEMJA

Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation0 sites40 target enrollmentNovember 27, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
Enrollment
40
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 27, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation

Eligibility Criteria

Inclusion Criteria

  • \- Male or female aged \= 18 years
  • \- Signed and dated informed consent for participation in the study
  • \- Total bilateral limbal stem\-cell deficiency
  • \- Caused by thermal or chemical burn, cornea transplantation, and other bilateral disorders of the ocular surface
  • \- Severe loss of vision (\<2/10 on decimal scale or/and EDTRS)
  • \- The subject must be covered by a social security system
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 20

Exclusion Criteria

  • \- Eye inflammation
  • \- Strictly unilateral ocular affliction
  • \- Acute systemic infection, objectified during consultation by the investigator and on the following paraclinical parameters: Erythrocyte Sedimentation Rate (ERS), C Reactive Protein rate
  • \- History of acute phase of ocular inflammation in the previous year
  • \- History of neoplasic disease
  • \- Glaucoma defined as intra ocular pressure (air tonometer and applanation tonometer) \= 22mmHg
  • \- Total symblepharon (comprising eyelid aperture): impossibility to open the 2 eyes
  • \- History of hyper sensibility or allergy to antibiotics or serum
  • \- Women who are or may be pregnant or breastfeading
  • \- Patients with any infectious disease (HBV, HCV, HIV, HTLV\-1 and syphilis)

Outcomes

Primary Outcomes

Not specified

Similar Trials